Replimune Group, Inc. SEC filings REPL

Replimune Group, Inc. has 657 filings in SEC EDGAR's recent list, going back to May 3, 2018. Its latest annual report, Form ARS, was filed on Jul 29, 2026 for the period ended Mar 31, 2026. The latest quarterly report (Form 10-Q) was filed on Oct 28, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 28, 2026 (results of operations). The company's fiscal year ends on March 31.

Form Description Filed Period
ARS Annual report to shareholders Jul 29, 2026 Mar 31, 2026
10-K Annual report Jun 29, 2026 Mar 31, 2026
ARS Annual report to shareholders Jul 25, 2025 Mar 31, 2025
10-K Annual report May 22, 2025 Mar 31, 2025
ARS Annual report to shareholders Jul 19, 2024 Mar 31, 2024
10-K Annual report May 16, 2024 Mar 31, 2024
ARS Annual report to shareholders Jul 26, 2023 Mar 31, 2023
10-K Annual report May 18, 2023 Mar 31, 2023
10-K Annual report May 19, 2022 Mar 31, 2022
10-K Annual report May 20, 2021 Mar 31, 2021
10-K Annual report Jun 3, 2020 Mar 31, 2020
10-K/A Amended annual report Jul 29, 2019 Mar 31, 2019
10-K Annual report Jun 28, 2019 Mar 31, 2019

Showing 13 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
REPL (Nasdaq)
Fiscal year ends
March 31
Incorporated in
DE
Headquarters
Woburn, MA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1737953

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.